帕金森病首次与复发性跌倒的预测模型
研究基于PPMI队列开发并外部验证帕金森病次年跌倒预测模型,首次跌倒模型含MDS-UPDRS Part III、MoCA与GDS,复发模型含H&Y、GDS与SDMT;两模型判别能力中等,外部验证中有所下降,探索性生物标志物仅开发队列有轻度增益。
要点
- 临床量表模型可中等程度识别帕金森病次年跌倒风险。
- 外部验证中模型判别能力下降,需谨慎推广。
- 影像与体液标志物的增量价值未获外部验证支持。
核心结论
- 临床指标可中等程度识别帕金森病次年跌倒风险,但外部验证中判别能力下降。
- 探索性生物标志物在开发队列有轻度增量价值,外部验证未体现。
研究设计与样本
- 在PPMI开发预测模型,并在UPenn队列进行外部验证。
- 首次跌倒模型开发集773个访视对,验证集589个访视对。
- 复发跌倒模型开发集302个访视对,验证集137个访视对。
主要发现
- 首次跌倒模型AUROC在PPMI为0.704(95%CI 0.653-0.750),UPenn为0.630(95%CI 0.564-0.687)。
- 复发跌倒模型AUROC在PPMI为0.683(95%CI 0.623-0.753),UPenn为0.641(95%CI 0.538-0.732)。
- UPenn低至高危组首次跌倒风险由7.1%升至18.5%,复发跌倒率由22.2%升至65.0%。
关键数值与推荐
- 首次跌倒模型纳入MDS-UPDRS Part III、MoCA与GDS。
- 复发跌倒模型纳入H&Y分期、GDS与SDMT。
临床怎么用
- 可基于常规临床量表对帕金森病患者次年跌倒风险分层。
- 外部验证判别能力有限,模型用于个体决策前需本地校准。
局限性
- 外部验证中模型判别能力下降,探索性生物标志物分析估计不精确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and externally validate prediction models for next-year falls in Parkinson's disease (PD), and to evaluate the incremental value of imaging and fluid biomarkers. METHODS: We developed models in Parkinson's Progression Markers Initiative (PPMI) to predict next-year falls with external validation in University of Pennsylvania (UPenn) cohorts. We evaluated incident falls among visits without current or prior falls and recurrent falls among visits with current falls. We calculated area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), and development-derived risk strata. RESULTS: The incident model, comprising Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III, Montreal Cognitive Assessment, and Geriatric Depression Scale (GDS), was developed in 773 visit-pairs and validated in 589 visit-pairs. AUROC was 0.704 (95% confidence interval [CI] = 0.653-0.750) in PPMI and 0.630 (95% CI = 0.564-0.687) in UPenn. Incident fall risk increased from 7.1 to 18.5% across low- to high-risk groups in UPenn. The recurrent model, comprising Hoehn and Yahr (H&Y), GDS, and Symbol Digit Modalities Test, was developed in 302 visit-pairs and validated in 137 visit-pairs. AUROC was 0.683 (95% CI = 0.623-0.753) in PPMI and 0.641 (95% CI = 0.538-0.732) in UPenn. Recurrent fall rates increased from 22.2 to 65.0% across low- to high-risk groups in UPenn. Exploratory biomarker augmentation modestly improved discrimination beyond clinical models in PPMI, but not in external validation, where estimates were imprecise. INTERPRETATION: Clinical measures may identify next-year fall risk in PD with moderate discrimination, although performance attenuated in external validation. Exploratory biomarkers provided modest incremental value in development but not in external validation. ANN NEUROL 2026.
引用
- Vizcarra JA, Hefter K, Duong MT, et al. Prediction of First and Recurrent Falls in Parkinson's Disease. Ann Neurol. 2026. PMID: 42960478. doi:10.1002/ana.78400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。